Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kyverna Therapeutics, Inc. (KYTX : NSDQ)

• Company Description    Kyverna Therapeutics Inc. is a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. The company's lead product candidate includes KYV-101. Kyverna Therapeutics Inc. is based in EMERYVILLE, Calif. Number of Employees: 112

• Price / Volume Information    Yesterday's Closing Price: $3.57 Daily Weekly Monthly 20 Day Moving Average: 590,279 shares Shares Outstanding: 43.22 (millions) Market Capitalization: $154.29 (millions) Beta: 2.95 52 Week High: $11.40 52 Week Low: $1.78 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.18% -0.68% 12 Week 91.93% 61.44% Year To Date -4.55% -10.61%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5980 HORTON STREET SUITE 550 - EMERYVILLE,CA 94608 USA ph: 510-626-8331 fax: - investorrelations@kyvernatx.com https://kyvernatx.com

• General Corporate Information    Officers Warner Biddle - Chief Executive Officer and Director Ryan Jones - Chief Financial Officer Ian Clark - Director Fred E. Cohen - Director Mert Aktar - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 501976104 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 43.22 Most Recent Split Date: (:1) Beta: 2.95 Market Capitalization: $154.29 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.84 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.66 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.69 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 8.04% vs. Previous Quarter: -17.05% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -51.66 12/31/24 - -40.35 ROA 06/30/25 - - 03/31/25 - -45.92 12/31/24 - -36.50 Current Ratio 06/30/25 - - 03/31/25 - 7.44 12/31/24 - 8.61 Quick Ratio 06/30/25 - - 03/31/25 - 7.44 12/31/24 - 8.61 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 5.18 12/31/24 - 6.17 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.03 12/31/24 - 0.05

Powered by Zacks Investment Research ©